Estimating the risks and benefits of tamoxifen for prophylactic breast cancer chemoprevention in Korea

Journal of Breast Cancer

Volumn 15, Issue 1, 2012, Pages 51-56

  Kim, Dong Uk ^a   Min, Jun Won ^a   Kim, You Me ^a   Chang, Myung Chul ^a  

^a Dankook University College of Medicine   (South Korea)

Author keywords

Breast; Chemoprevention; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGED; BRAIN ISCHEMIA; BREAST CANCER; CANCER INVASION; CANCER PATIENT; CANCER PREVENTION; ENDOMETRIUM CANCER; FEMALE; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; KOREA; LUNG EMBOLISM; REVIEW; RISK BENEFIT ANALYSIS; STROKE; TREATMENT OUTCOME;

EID: 84859351724     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2012.15.1.51     Document Type: Review

References (10)

1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
2. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-46.
3. Kim SH, Chae YS, Son WJ, Shin DJ, Kim YM, Chang MC. Estimation of individualized probabilities of developing breast cancer for Korean women. J Korean Surg Soc 2008;74:405-11.
4. Kang HY, Yang KH, Kim YN, Moon SH, Choi WJ, Kang DR, et al. Incidence and mortality of hip fracture among the elderly population in South Korea: a population-based study using the national health insurance claims data. BMC Public Health 2010;10:230.
5. Jee SH, Park JW, Lee SY, Nam BH, Ryu HG, Kim SY, et al. Stroke risk prediction model: a risk profile from the Korean study. Atherosclerosis 2008;197:318-25.
6. Ministry for Health, Welfare and Family Affairs, Korea Central Cancer Registry. Cancer Incidence in Korea 1999-2002. Goyang: Korea Central Cancer Registry; 2008. p.76-7.
7. Statistics of deaths by cause. Korean Statistical Information Service. http://www.kosis.kr/. Accessed August 1st, 2011.
8. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-32.
9. Waters EA, Cronin KA, Graubard BI, Han PK, Freedman AN. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev 2010;19:443-6.
10. Choi WI, Lee MY, Oh D, Rho BH, Hales CA. Estimated incidence of acute pulmonary embolism in a Korean hospital. Clin Appl Thromb Hemost 2011;17:297-301.